Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma

Angiogenesis plays an important role in multiple myeloma (MM) progression. Various mitogens such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) have been implicated in the angiogenic process of various malignancies. Interleukin-6 (IL-6) is a growth factor of...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2003, Vol.82 (1), p.19-23
Main Authors: ALEXANDRAKIS, M. G, PASSAM, F. H, BOULA, A, CHRISTOPHORIDOU, A, ALOIZOS, G, ROUSSOU, P, KYRIAKOU, D. S
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers - blood
Case-Control Studies
Endothelial Growth Factors - blood
Female
Fibroblast Growth Factor 2 - blood
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Intercellular Signaling Peptides and Proteins - blood
Lymphokines - blood
Male
Medical sciences
Middle Aged
Multiple Myeloma - blood
Multiple Myeloma - pathology
Neovascularization, Pathologic - blood
Prognosis
Receptors, Interleukin-6 - blood
Severity of Illness Index
Solubility
Tumor Necrosis Factor-alpha - analysis
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis plays an important role in multiple myeloma (MM) progression. Various mitogens such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) have been implicated in the angiogenic process of various malignancies. Interleukin-6 (IL-6) is a growth factor of myeloma cells and its signaling is mediated via a cell surface receptor complex (IL-6r). IL-6 and tumor necrosis factor-alpha (TNF-alpha) are involved in the secretion of VEGF by IL-6r expressing myeloma cells. In this study, serum FGF-2, VEGF, IL-6r, and TNF-alpha were measured in 46 untreated MM patients and were studied in relation to disease stage (by Salmon-Durie criteria) and severity [assessed by serum beta(2)-microglobulin (beta(2)M), C-reactive protein (CRP), alpha(1)-antitrypsin (alpha(1)AT), and lactic dehydrogenase (LDH) levels]. The results showed that FGF-2, VEGF, IL-6r, and TNF-alpha were significantly elevated in MM patients in comparison to controls ( p
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-002-0558-0